nitric oxide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-24 and is reviewed periodically as new material appears.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
== Modes of delivery == There are three general categories of DNA construct delivery: physical, chemical, and viral. Physical methods, which deliver the DNA by physically penetrating the cell, include microinjection, electroporation, and biolistics. Chemical methods rely on chemical reactions to deliver the DNA and include transformation with cells made competent using calcium phosphate as well as delivery via lipid nanoparticles. Viral methods use a variety of viral vectors to deliver the DNA, including adenovirus, lentivirus, and herpes simplex virus
In his book TiHKAL (Tryptamines I Have Known and Loved) and other publications, Alexander Shulgin lists DMT's dose as greater than 350 mg orally, 60 to 100 mg intramuscularly, subcutaneously, or via smoking, and 4 to 30 mg by intravenous injection. He also reported that doses of 150 to 350 mg or even up to 1,000 mg orally and a dose of 100 mg buccally produced no effects, whereas doses of 20 to 80 mg intramuscularly, 30 to 100 mg smoked, and 15 to 30 mg intravenously were all active in producing effects. In terms of intramuscular injection, threshold effects occur at a dose of 30 mg and full effects occur at a dose of 50 to 100 mg by this route. Similarly, the dose for full effects with subcutaneous injection is likewise 60 to 100 mg. With regard to intravenous injection, a dose of 4 mg was indistinguishable from placebo, 8 mg produced physical effects but no psychoactive effects, 15 mg produced threshold psychedelic effects, and 30 mg produced strong psychedelic effects. Shulgin lists the duration of parenteral DMT alone as up to 1 hour. In other more recent publications, different dose ranges of inhaled DMT of 2 to 100 mg or 15 to 60 mg have been described and typical doses have been reported to be 40 to 50 mg. Concerning intravenous injection and based on contemporary clinical studies, 15 mg has been described as a low dose, 25 mg as an intermediate or "good effect" dose, and 30 mg as a high or "ego-dissolution" dose. There may be a ceiling in the intensity of DMT's effects however, with saturation reached at doses of 15 to 20 mg.
Narrated by Paul Daneman, directed by Julian Nott, made by Peninsula Films 9 October The Rubber Universe, in 1929 Hubble's law was discovered, but the Hubble constant was not fully known - about the Hubble constant, which could be between 50 and 85, which meant that the universe could be 14 billion years old, not 8 billion years old, for a constant of 50; scientists were highly protective of any discoveries that they made, or not, but that did not always lead to good outcomes for all concerned - such as the relationship between Allan Sandage, who thought the Hubble constant was about 50, and the French Gérard de Vaucouleurs; Canadian Sidney van den Bergh looked at the Hubble constant as well; Tod R.
Epitalon is a synthetic peptide, telomerase activator, and putative anti-aging compound, which was identified as the putative active component of a bovine pineal gland extract known as epithalamin. Most studies on epitalon and epithalamin have been conducted by the St. Petersburg Institute of Bioregulation and Gerontology, primarily overseen by Vladimir Khavinson, in Russia, though in recent years research using epitalon has started to be conducted elsewhere, focusing mainly on its ability to extend telomere length.
Sources: en.wikipedia.org
==== Diarrhea ==== In cases of diarrhea-predominate irritable bowel syndrome, opioids may be used to suppress diarrhea. Loperamide is a peripherally selective opioid available without a prescription used to suppress diarrhea. The ability to suppress diarrhea also produces constipation when opioids are used beyond several weeks.
== Early life, education and career == Moroder studied chemistry at the University of Padova, where he graduated 1965 in chemistry with the doctoral thesis on synthesis of S-peptide of ribonuclease A in the laboratory of Ernesto Scoffone at the Institute of Organic Chemistry. In 1968 he joined Klaus H. Hofmann's Group at the University of Pittsburgh to work on chemical synthesis of the peptidic adrenocorticotropic hormone and its derivatives. Moroder habilitated in 1971 at the University of Padova in Chemistry of Natural Products. 1975 he became a senior research fellow in the Department of Peptide Chemistry at the Max Planck Institute for Biochemistry (MPIB) in Martinsried headed by Erich Wünsch. Between 1991 and 2008 he was the head of the Laboratory of Bioorganic chemistry at the MPIB. Since 1994 he was an adjunct professor at the Technical University of Munich.
A coroner's inquest into the deaths of Lancashire couple John and Susan Cooper, who died while on holiday in Egypt in August 2018, concludes their deaths occurred as a result of carbon monoxide poisoning brought about by the use of a substance containing dichloromethane to kill bed bugs in an adjoining hotel room. 13 November – Police confirm that three children are among five members of the same family to have been killed in a house fire in London the previous day. A sixth person subsequently dies in hospital a few days later. 14 November – Around 400 are evacuated from Barton House, the oldest tower block in Bristol, after a survey carried out by Bristol City Council identified structural and fire safety concerns with the building. 16 November – The Department for Education asks the exams regulator, Ofqual, to extend extra support for GCSE students in England for another year as a way to help against the impact of COVID-19 on students taking examinations. Convicted murderer Ron Evans, 82, also known as the Clifton Rapist, is sentenced to four years in prison after he was earlier convicted of sexually assaulting a woman he met at a community centre. Cumbria Police confirm that a 16-year-old boy arrested in connection with the felling of the Sycamore Gap tree will face no further action. Two 12-year-old boys are charged with the murder of 19-year-old Shawn Seesahai, who was fatally stabbed in Wolverhampton three days earlier.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.